Clinical Observation On Prevention Of Aromatase Inhibitor-Associated Bone Loss In Postoperative Breast Cancer With Modified Astragalus Membranaceus Decoction

Objective:The aim of this study was to evaluate the preventive and therapeutic effects of modified astragalus membranaceus decoction on Aromatase Inhibitor-Associated Bone Loss after breast cancer surgery from bone mineral density,incidence of osteoporosis,bone pain grade,quality of life score and medication compliance score,so as to provide basis for early intervention in bone loss and clinical treatment.Methods:This subject adopts a prospective,randomized and controlled clinical research methods.We included 125 patients of early breast cancer who were admitted to the mammary department in Shuguang hospital affiliated to Shanghai University of Traditional Chinese Medicine and in Ruijin Hospital affiliated with Shanghai Jiaotong University School from August 2016 to January 2019.The patients were randomly divided into the treatment group of 62 cases and the control group of 63 cases.All patients were treated with aromatase inhibitor orally.The treatment group was treated with modified astragalus membranaceus decoction and aromatase inhibitor.We observed and recorded the bone mineral density,the incidence of osteoporosis,the grade of bone pain,the score of quality of life and the score of medication compliance before treatment,6 months after treatment and 12 months after treatment.Results:1.Bone mineral density:6 months after treatment and 12 months after treatment,the bone mineral density of lumbar spine,femoral neck and total hip in the control group was significantly lower than that in the treatment group,but there was no significant difference between the two groups(P>0.05).It can not be considered that there were differences in bone mineral density between the two groups at different time points.2.Incidence of osteoporosis:6 months after treatment and 12 months after treatment,the incidence of osteoporosis in the treatment group was 3.39%,1.76%,and that in the control group was 4.91%,3.45%.There was no significant difference in the incidence of osteoporosis between the two groups(P>0.05).3.Bone pain grade:6 months after treatment and 12 months after treatment,there was a significant difference between the two groups(P<0.05).Bone pain grade in the treatment group was significantly lower than the control group.It can be concluded that modified astragalus membranaceus decoction can effectively reduce bone pain level and relieve clinical bone pain symptoms.4.Quality of life score:6 months after treatment and 12 months after treatment,the quality of life score in the treatment group was significantly higher than that in the control group,and there was a significant difference between the two groups(P<0.05).This shows that modified astragalus membranaceus decoction can effectively improve the quality of life of patients.5.Medication compliance score:12 months after treatment,the medication adherence score of the treatment group was significantly higher than that of the control group,and the difference between the groups was statistically significant(P<0.05).It can be considered that modified astragalus membranaceus decoction can effectively improve the patient's medication compliance.Conclusions:modified astragalus membranaceus decoction can reduce the trend of bone mineral density decline,effectively prevent and alleviate clinical symptoms such as bone pain,joint soreness,significantly optimize the quality of life of patients,improve their compliance with medication.